SavedAdd your journal

Journals / Anadolu Kardiyoloji Dergisi / 2013 / Cilt: 13 - Sayı: 8

Almanac 2013: acute coronary syndromes

Almanac 2013: akut koroner sendromları

Pascal MEIER
J. Alexandra LANSKY
Andreas BAUMBACH
Pages
825–832
Publication Date
2022-10-10
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

This trend is likely to continue based on recent therapeutic progress which includes novel anti- platelet agents such as prasugrel, ticagrelor, and cangrelor.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Unstable coronary artery plaque is the most common underlying cause of acute coronary syndromes (ACS) and can manifest as unstable angina, non-ST segment elevation infarction (NSTE-ACS), and ST elevation myocardial infarction (STEMI), but can also manifest as sudden cardiac arrest due to ischaemia induced tachyarrhythmias.
📊
Key Findings & Data:ACS mortality has decreased significantly over the last few years, especially from the more extreme manifestations of ACS, STEMI, and cardiac arrest.
💡
Conclusion & Impact:This trend is likely to continue based on recent therapeutic progress which includes novel anti- platelet agents such as prasugrel, ticagrelor, and cangrelor.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Unstable coronary artery plaque is the most common underlying cause of acute coronary syndromes (ACS) and can manifest as unstable angina, non-ST segment elevation infarction (NSTE-ACS), and ST elevation myocardial infarction (STEMI), but can also manifest as sudden cardiac arrest due to ischaemia induced tachyarrhythmias. ACS mortality has decreased significantly over the last few years, especially from the more extreme manifestations of ACS, STEMI, and cardiac arrest. This trend is likely to continue based on recent therapeutic progress which includes novel anti- platelet agents such as prasugrel, ticagrelor, and cangrelor.

Özet

Unstable coronary artery plaque is the most common underlying cause of acute coronary syndromes (ACS) and can manifest as unstable angina, non-ST segment elevation infarction (NSTE-ACS), and ST elevation myocardial infarction (STEMI), but can also manifest as sudden cardiac arrest due to ischaemia induced tachyarrhythmias. ACS mortality has decreased significantly over the last few years, especially from the more extreme manifestations of ACS, STEMI, and cardiac arrest. This trend is likely to continue based on recent therapeutic progress which includes novel anti- platelet agents such as prasugrel, ticagrelor, and cangrelor.

🔖

Cite This Article

MEIER, P., LANSKY, J. A., BAUMBACH, A. (2022). Almanac 2013: acute coronary syndromes. Anadolu Kardiyoloji Dergisi, Cilt: 13 - Sayı: 8, 825–832. https://ajindex.com/articles/436265

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (12)

  1. Members WG, Roger VL, Go AS, et al. Heart disease and stroke statistics-2012 update: a report from the American Heart Association. Circulation 2012
  2. e2-220. [CrossRef] 2. Knight CJ, Timmis AD. Almanac 2011: acute coronary syn- dromes. The national society journals present selected research that has driven recent advances in clinical cardiology. Heart 2011
  3. [CrossRef] 3. Yeh RW, Sidney S, Chandra M, et al. Population trends in the inci- dence and outcomes of acute myocardial infarction. N Engl J Med 2010
  4. [CrossRef] 4. Nolan JP Lyon RM, Sasson C, et al. Advances in the hospital man- agement of patients following an out of hospital cardiac arrest. Heart 2012
  5. [CrossRef] 5. Fothergill RT, Watson LR, Chamberlain D, et al. Increases in sur- vival from out-of-hospital cardiac arrest: a five year study. Resuscitation 2013
  6. [CrossRef] 6. Stone GW, Maehara A, Witzenbichler B, et al. Intracoronary abcix- imab and aspiration thrombectomy in patients with large anterior myocardial infarction: the INFUSE-AMI randomized trial. JAMA 2012
  7. [CrossRef] 7. Stone GW, Witzenbichler B, Guagliumi G, et al. Heparin plus a glycoprotein IIb/IIIa inhibitor versus bivalirudin monotherapy and paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction (HORIZONS-AMI): final 3-year results from a multicentre, randomised controlled trial. Lancet 2011
  8. [CrossRef] 8. Kimmelstiel C, Zhang P Kapur NK, et al. Bivalirudin is a dual inhibi- tor of thrombin and collagen-dependent platelet activation in patients undergoing percutaneous coronary intervention. Circ Cardiovasc Interv 2011
  9. [CrossRef] 9. Meier P Frohlich GM, Lansky AJ. Bleeding complications in percuta- neous coronary interventions. Cardiology 2013
  10. [CrossRef] 10. Mamas MA, Ratib K, Routledge H, et al. Influence of access site selec- tion on PCI-related adverse events in patients with STEMI: meta-analy- sis of randomised controlled trials. Heart 2012
  11. [CrossRef] 11. Meier P Windecker S, Lansky AJ. Radial versus femoral access for primary percutaneous coronary intervention: is there a preferred route to the heart? Heart 2012
  12. [CrossRef] 12. Baklanov DV, Kaltenbach LA, Marso SP et al. The prevalence and outcomes of transradial percutaneous coronary intervention for ST-segment elevation myocardial infarction: analysis from the National Cardiovascular Data Registry (2007 to 2011). J Am Coll Cardiol 2013